Research Advances on Mechanisms and Interventions of DNA Methylation-Regulated Aging-Related Imbalance in Bone Metabolism
Abstract
Aging can induce age-related bone diseases such as osteoporosis. DNA methylation, a core epigenetic regulatory mechanism, participate in the pathological process of aging-induced bone metabolism imbalance by modulating gene expression at the epigenetic level. Using S-adenosylmethionine as a methyl donor, it exhibits characteristics of hypomethylation in genomic repetitive regions and abnormal methylation in CpG islands of promoters of key bone metabolism genes with advancing age. The "epigenetic clock" constructed based on these features can accurately predict an individual's biological age. In bone metabolism, DNA methylation disrupts the osteoblast-osteoclast balance by targeting key factors. Such abnormalities are driven by aging-related inflammation and oxidative stress, while bone loss feedback exacerbates epigenetic disorders, forming a vicious cycle. Targeted intervention strategies have demonstrated significant potential in addressing bone metabolism-related issues. Low-dose DNA methyltransferase inhibitors can improve bone metabolism; nutrients such as folate and cobalamin maintain methylation homeostasis by optimizing one-carbon metabolism pathways; while CRISPR/dCas technology enables precise regulation in the cellular and animal levels, thereby affecting bone metabolism. However, existing strategies still face challenges such as off-target effects and low delivery efficiency. Future research needs to deepen mechanistic studies, optimize intervention methods, and promote their translation into clinical prevention and treatment of osteoporosis.
Keywords: DNA methylation, Osteoporosis, Aging, Osteoblasts, Osteoclasts, Epigenetic clock
Full Text:
PDFReferences
Tang J R, Li B, Liu Y K, et al. Research progress on the relationship between senescent cells and bone-related diseases[J]. Stomatol, 2025, 45(2): 134-138. DOI: 10.13591/j.cnki.kqyx.2025.02.010.
Grote C, Reinhardt D, Zhang M, et al. Regulatory mechanisms and clinical manifestations of musculoskeletal aging[J]. J Orthop Res, 2019, 37(7): 1475-1488. DOI: 10.1002/jor.24292.
Wang K, Liu H, Hu Q, et al. Epigenetic regulation of aging: implications for interventions of aging and diseases[J/OL]. Signal Transduct Target Ther, 2022, 7(1): 374. https://doi.org/10.1038/s41392-022-01211-8.
Zhang L, Tian R T, Wang Z W, et al. Research progress on DNA methylation age prediction[J]. J Biomed Eng Prog, 2023, 44(4): 357-363. Koch Z, Li A, Evans D S, et al. Somatic mutation as an explanation for epigenetic aging[J]. Nat Aging, 2025, 5(4): 709-719. DOI: 10.1038/s43587-024-00794-x.
Yao P C, Guan Y L, Ma B X, et al. Research progress on DNA methylation in exploring traditional Chinese medicine intervention for osteoporosis[J]. Chin J Osteoporos, 2023, 29(8): 1220-1224.
Wang J, Li Y, Wang S, et al. Exploring the therapeutic mechanism of deer antler traditional Chinese medicine compound on ovariectomized osteoporosis rats based on Runx2 and Osterix promoter methylation in bone tissue[J]. World Sci Technol-Mod Tradit Chin Med, 2020, 22(5): 1744-1749.
Cicali K A, Jara C, Cortés-díaz D, et al. Unraveling sex differences in age-related hippocampal decline: differential mitochondrial dysfunction, Lonp1-dependent mitochondrial proteostasis and mtROS production in aged C57BL/6 mice[J/OL]. Cell Death Dis, 2025, 17(1): 155. https://doi. org/10.1038/s41419-025-08360-y.
Khosla S, Farr J N, Tchkonia T, et al. The role of cellular senescence in ageing and endocrine disease[J]. Nat Rev Endocrinol, 2020, 16(5): 263-275. DOI: 10.1038/s41574-020-0335-y.
Li K, Hu S, Chen H. Cellular senescence and other age-related mechanisms in skeletal diseases[J/OL]. Bone Res, 2025, 13(1): 68. https://doi.org/10.1038/s41413-025-00448-7.
Kroemer G, Maier A B, Cuervo A M, et al. From geroscience to precision geromedicine: understanding and managing aging[J]. Cell, 2025, 188(8): 2043-2062. DOI: 10.1016/j.cell.2025.03.011.
Kiselev I S, Baulina N M, Favorova O O. Epigenetic clock: DNA methylation as a marker of biological age and age-associated diseases[J]. Biochemistry (Mosc), 2025, 90(Suppl 1): S356-S372. DOI: 10.1134/s0006297924602843.
Lafont J E, Moustaghfir S, Durand A L, et al. The epigenetic players and the chromatin marks involved in the articular cartilage during osteoarthritis[J/OL]. Front Physiol, 2023, 14: 1070241. https://doi.org/10. 3389/fphys.2023.1070241.
Bouyahya A, Mechchate H, Oumeslakht L, et al. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions[J/OL]. Biomolecules, 2022, 12(3): 367. https://doi.org/10.3390/biom12030367.
Davletgildeeva A T, Kuznetsov N A. The role of dnmt methyltransferases and tet dioxygenases in the maintenance of the dna methylation level[J/OL]. Biomolecules, 2024, 14(9): 1117. https://doi.org/10.3390/biom14091117.
Wagih N, Abdel-rahman I M, El-koussi N A, et al. Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article[J].
RSC Adv, 2025, 15(2): 966-1010. DOI: 10.1039/d4ra05014b. Lai Z, Shu Q, Song Y, et al. Effect of DNA methylation on the osteogenic differentiation of mesenchymal stem cells: concise review[J/OL]. Front Genet, 2024, 15: 1429844. https://doi.org/10.3389/fgene.2024.1429844.
Prosz A, Pipek O, Börcsök J, et al. Biologically informed deep learning for explainable epigenetic clocks[J/OL]. Sci Rep, 2024, 14(1): 1306. https://doi.org/10.1038/s41598-023-50495-5.
Crofts S J C, Latorre-crespo E, Chandra T. DNA methylation rates scale with maximum lifespan across mammals[J]. Nat Aging, 2024, 4(1): 27-32. DOI: 10.1038/s43587-023-00535-6.
Horvath S. DNA methylation age of human tissues and cell types[J/OL]. Genome Biol, 2013, 14(10): R115. https://doi.org/10.1186/gb-2013-14-10-r115.
Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates[J]. Mol Cell, 2013, 49(2): 359-367. DOI: 10.1016/j.molcel.2012.10.016.
Levine M E, Lu A T, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan[J]. Aging (Albany NY), 2018, 10(4): 573-591. DOI: 10.18632/aging.101414.
Duan R, Fu Q, Sun Y, et al. Epigenetic clock: a promising biomarker and practical tool in aging[J/OL]. Ageing Res Rev, 2022, 81: 101743. https://doi.org/10.1016/j.arr.2022.101743.
Lu A T, Quach A, Wilson J G, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan[J]. Aging (Albany NY), 2019, 11(2): 303-327. DOI: 10.18632/aging.101684.
Jo B K, Lee S Y, Eom H J, et al. Organ-specific dedifferentiation and epigenetic remodeling in in vivo reprogramming[J/OL]. Aging Cell, 2025, 24(11): e70268. https://onlinelibrary.wiley.com/doi/10.1111/acel.70268/. DOI: 10.1111/acel.70268.
Bonder M J, Clark S J, Krueger F, et al. scEpiAge: an age predictor highlighting single-cell ageing heterogeneity in mouse blood[J/OL]. Nat Commun, 2024, 15(1): 7567. https://doi.org/10.1038/s41467-024-51833-5.
Hojo H. Emerging RUNX2-mediated gene regulatory mechanisms consisting of multi-layered regulatory networks in skeletal development [J/OL]. Int J Mol Sci, 2023, 24(3): 2979. https://doi.org/10.3390/ijms24032979.
Zhao J, Chen A, Wang R, et al. Bmi-1 epigenetically orchestrates osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells to delay bone aging[J/OL]. Adv Sci (Weinh), 2024, 11(46): e2404518. https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs. 202404518. DOI: 10.1002/advs.202404518.
Wang L, You X, Ruan D, et al. TET enzymes regulate skeletal development through increasing chromatin accessibility of RUNX2 target genes[J/OL]. Nat Commun, 2022, 13(1): 4709. https://doi.org/10.1038/s41467-022-32138-x.
Wu L, Wang L, Zhuang Y, et al. Integrative analysis reveals synergistic regulation of Sp7 by BRD9 and Wnt/β-catenin signaling during osteogenic differentiation[J/OL]. Commun Biol, 2025, 9(1): 23. https://doi.org/10.1038/s42003-025-09278-z.
Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation[J]. Cell, 2002, 108(1): 17-29. DOI: 10.1016/s0092-8674 (01)00622-5.
Xiao Z S, Hjelmeland A B, Quarles L D. Selective deficiency of the "bone-related" Runx2-Ⅱunexpectedly preserves osteoblast-mediated skeletogenesis[J]. J Biol Chem, 2004, 279(19): 20307-20313. DOI: 10.1074/jbc.M401109200.
Han K, Wang F, Yu M, et al. Estrogen promotes osteogenic differentiation of bone marrow stem cells in patients with postmenopausal osteoporosis by elevating the expressions of Runx-2 and Osterix[J/OL]. Panminerva Med, 2020. https://www.minervamedica.it/en/journals/panminerva-medica/article.php?cod=R41Y9999N00A20012303. DOI: 10.23736/s0031-0808.19.03791-1.
Ortuño M J, Susperregui A R, Artigas N, et al. Osterix induces Col1a1 gene expression through binding to Sp1 sites in the bone enhancer and proximal promoter regions[J]. Bone, 2013, 52(2): 548-556. DOI: 10.1016/j. bone.2012.11.007.
Sinha K M, Yasuda H, Zhou X, et al. Osterix and NO66 histone demethylase control the chromatin of Osterix target genes during osteoblast differentiation[J]. J Bone Miner Res, 2014, 29(4): 855-865. DOI: 10.1002/jbmr.2103.
Fabre S, Bourmaud M, Mabilleau G, et al. Lrp5 p.Val667Met variant compromises bone mineral density and matrix properties in osteoporosis[J/OL]. JBMR Plus, 2023, 7(6): e10741. https://academic.oup.
Refbacks
- There are currently no refbacks.
